4/12
08:00 am
arqt
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $16.00 price target on the stock.
High
Report
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $16.00 price target on the stock.
4/10
08:13 am
arqt
Arcutis Appoints David Topper as Chief Financial Officer [Yahoo! Finance]
Low
Report
Arcutis Appoints David Topper as Chief Financial Officer [Yahoo! Finance]
4/10
08:00 am
arqt
Arcutis Appoints David Topper as Chief Financial Officer
Medium
Report
Arcutis Appoints David Topper as Chief Financial Officer
4/5
04:00 pm
arqt
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
High
Report
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/28
08:00 am
arqt
Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference
Low
Report
Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference
3/19
12:08 pm
arqt
Arcutis Biotherapeutics, Inc. (ARQT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now [Yahoo! Finance]
Low
Report
Arcutis Biotherapeutics, Inc. (ARQT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now [Yahoo! Finance]
3/11
08:16 am
arqt
Arcutis Promotes Todd Tucker to Chief Human Resources Officer [Yahoo! Finance]
High
Report
Arcutis Promotes Todd Tucker to Chief Human Resources Officer [Yahoo! Finance]
3/11
08:00 am
arqt
Arcutis Promotes Todd Tucker to Chief Human Resources Officer
High
Report
Arcutis Promotes Todd Tucker to Chief Human Resources Officer
3/10
04:15 pm
arqt
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting [Yahoo! Finance]
Medium
Report
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting [Yahoo! Finance]
3/10
04:00 pm
arqt
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
Medium
Report
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
3/9
04:03 pm
arqt
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction [Yahoo! Finance]
Medium
Report
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction [Yahoo! Finance]
3/9
04:00 pm
arqt
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
Medium
Report
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
3/5
04:10 pm
arqt
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Medium
Report
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
3/5
04:00 pm
arqt
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/4
04:00 pm
arqt
Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Low
Report
Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
3/4
08:16 am
arqt
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting [Yahoo! Finance]
High
Report
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting [Yahoo! Finance]
3/4
08:00 am
arqt
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting
Medium
Report
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting
3/1
12:03 pm
arqt
Wall Street Analysts See a 58.85% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High? [Yahoo! Finance]
Low
Report
Wall Street Analysts See a 58.85% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High? [Yahoo! Finance]
3/1
11:10 am
arqt
Is Arcutis Biotherapeutics (ARQT) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]
Medium
Report
Is Arcutis Biotherapeutics (ARQT) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]
3/1
06:34 am
arqt
Earnings Beat: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts [Yahoo! Finance]
High
Report
Earnings Beat: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts [Yahoo! Finance]
2/29
05:00 pm
arqt
Arcutis to Present at the TD Cowen 44th Annual Health Care Conference
High
Report
Arcutis to Present at the TD Cowen 44th Annual Health Care Conference
2/29
11:43 am
arqt
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/29
06:19 am
arqt
Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues [Yahoo! Finance]
Low
Report
Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues [Yahoo! Finance]
2/29
05:15 am
arqt
Arcutis announces pricing of $150 million public offering [Seeking Alpha]
Medium
Report
Arcutis announces pricing of $150 million public offering [Seeking Alpha]
2/28
11:30 pm
arqt
Arcutis Announces Pricing of $150 Million Public Offering
Medium
Report
Arcutis Announces Pricing of $150 Million Public Offering